Review



tocriscreen fda-approved drugs library  (Bio-Techne corporation)


Bioz Verified Symbol Bio-Techne corporation is a verified supplier
Bioz Manufacturer Symbol Bio-Techne corporation manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Bio-Techne corporation tocriscreen fda-approved drugs library
    Tocriscreen Fda Approved Drugs Library, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 95/100, based on 38 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda/Tocriscreen+FDA-Approved+Drugs+Library/custom%407200%4042085862
    Average 95 stars, based on 38 article reviews
    tocriscreen fda-approved drugs library - by Bioz Stars, 2026-11
    95/100 stars

    Images

    Related Articles

    Extraction:

    Article Title: Organoid Intelligent Morphomics: Decoding the organoid morphome through artificial intelligence from phenotypic quantification to mechanistic insight
    Article Snippet: ional capabilities that can be leveraged for PDS, facilitating objective evaluation of therapeutic efficacy. In a seminal study, kidney organoids were deployed to screen the FDA-approved drug library (Tocriscreen), where quantitative extraction of nephron segment parameters, including volume, cell number, and spatial density, revealed that imatinib markedly attenuated cisplatin-induced tubular dama

    Drug discovery:

    Article Title: Organoid Intelligent Morphomics: Decoding the organoid morphome through artificial intelligence from phenotypic quantification to mechanistic insight
    Article Snippet: ional capabilities that can be leveraged for PDS, facilitating objective evaluation of therapeutic efficacy. In a seminal study, kidney organoids were deployed to screen the FDA-approved drug library (Tocriscreen), where quantitative extraction of nephron segment parameters, including volume, cell number, and spatial density, revealed that imatinib markedly attenuated cisplatin-induced tubular dama

    Food & Beverages:

    Article Title: Organoid Intelligent Morphomics: Decoding the organoid morphome through artificial intelligence from phenotypic quantification to mechanistic insight
    Article Snippet: ional capabilities that can be leveraged for PDS, facilitating objective evaluation of therapeutic efficacy. In a seminal study, kidney organoids were deployed to screen the FDA-approved drug library (Tocriscreen), where quantitative extraction of nephron segment parameters, including volume, cell number, and spatial density, revealed that imatinib markedly attenuated cisplatin-induced tubular dama

    Suspension:

    Article Title: Organoid Intelligent Morphomics: Decoding the organoid morphome through artificial intelligence from phenotypic quantification to mechanistic insight
    Article Snippet: ional capabilities that can be leveraged for PDS, facilitating objective evaluation of therapeutic efficacy. In a seminal study, kidney organoids were deployed to screen the FDA-approved drug library (Tocriscreen), where quantitative extraction of nephron segment parameters, including volume, cell number, and spatial density, revealed that imatinib markedly attenuated cisplatin-induced tubular dama

    Transduction:

    Article Title: Organoid Intelligent Morphomics: Decoding the organoid morphome through artificial intelligence from phenotypic quantification to mechanistic insight
    Article Snippet: ional capabilities that can be leveraged for PDS, facilitating objective evaluation of therapeutic efficacy. In a seminal study, kidney organoids were deployed to screen the FDA-approved drug library (Tocriscreen), where quantitative extraction of nephron segment parameters, including volume, cell number, and spatial density, revealed that imatinib markedly attenuated cisplatin-induced tubular dama

    Cell Culture:

    Article Title: Organoid Intelligent Morphomics: Decoding the organoid morphome through artificial intelligence from phenotypic quantification to mechanistic insight
    Article Snippet: ional capabilities that can be leveraged for PDS, facilitating objective evaluation of therapeutic efficacy. In a seminal study, kidney organoids were deployed to screen the FDA-approved drug library (Tocriscreen), where quantitative extraction of nephron segment parameters, including volume, cell number, and spatial density, revealed that imatinib markedly attenuated cisplatin-induced tubular dama

    Control:

    Article Title: Organoid Intelligent Morphomics: Decoding the organoid morphome through artificial intelligence from phenotypic quantification to mechanistic insight
    Article Snippet: ional capabilities that can be leveraged for PDS, facilitating objective evaluation of therapeutic efficacy. In a seminal study, kidney organoids were deployed to screen the FDA-approved drug library (Tocriscreen), where quantitative extraction of nephron segment parameters, including volume, cell number, and spatial density, revealed that imatinib markedly attenuated cisplatin-induced tubular dama

    Polymerase Chain Reaction:

    Article Title: Organoid Intelligent Morphomics: Decoding the organoid morphome through artificial intelligence from phenotypic quantification to mechanistic insight
    Article Snippet: ional capabilities that can be leveraged for PDS, facilitating objective evaluation of therapeutic efficacy. In a seminal study, kidney organoids were deployed to screen the FDA-approved drug library (Tocriscreen), where quantitative extraction of nephron segment parameters, including volume, cell number, and spatial density, revealed that imatinib markedly attenuated cisplatin-induced tubular dama

    Modification:

    Article Title: Organoid Intelligent Morphomics: Decoding the organoid morphome through artificial intelligence from phenotypic quantification to mechanistic insight
    Article Snippet: ional capabilities that can be leveraged for PDS, facilitating objective evaluation of therapeutic efficacy. In a seminal study, kidney organoids were deployed to screen the FDA-approved drug library (Tocriscreen), where quantitative extraction of nephron segment parameters, including volume, cell number, and spatial density, revealed that imatinib markedly attenuated cisplatin-induced tubular dama

    Reverse Transcription:

    Article Title: Organoid Intelligent Morphomics: Decoding the organoid morphome through artificial intelligence from phenotypic quantification to mechanistic insight
    Article Snippet: ional capabilities that can be leveraged for PDS, facilitating objective evaluation of therapeutic efficacy. In a seminal study, kidney organoids were deployed to screen the FDA-approved drug library (Tocriscreen), where quantitative extraction of nephron segment parameters, including volume, cell number, and spatial density, revealed that imatinib markedly attenuated cisplatin-induced tubular dama

    Real-time Polymerase Chain Reaction:

    Article Title: Organoid Intelligent Morphomics: Decoding the organoid morphome through artificial intelligence from phenotypic quantification to mechanistic insight
    Article Snippet: ional capabilities that can be leveraged for PDS, facilitating objective evaluation of therapeutic efficacy. In a seminal study, kidney organoids were deployed to screen the FDA-approved drug library (Tocriscreen), where quantitative extraction of nephron segment parameters, including volume, cell number, and spatial density, revealed that imatinib markedly attenuated cisplatin-induced tubular dama

    Incubation:

    Article Title: Organoid Intelligent Morphomics: Decoding the organoid morphome through artificial intelligence from phenotypic quantification to mechanistic insight
    Article Snippet: ional capabilities that can be leveraged for PDS, facilitating objective evaluation of therapeutic efficacy. In a seminal study, kidney organoids were deployed to screen the FDA-approved drug library (Tocriscreen), where quantitative extraction of nephron segment parameters, including volume, cell number, and spatial density, revealed that imatinib markedly attenuated cisplatin-induced tubular dama

    Quantitative RT-PCR:

    Article Title: Organoid Intelligent Morphomics: Decoding the organoid morphome through artificial intelligence from phenotypic quantification to mechanistic insight
    Article Snippet: ional capabilities that can be leveraged for PDS, facilitating objective evaluation of therapeutic efficacy. In a seminal study, kidney organoids were deployed to screen the FDA-approved drug library (Tocriscreen), where quantitative extraction of nephron segment parameters, including volume, cell number, and spatial density, revealed that imatinib markedly attenuated cisplatin-induced tubular dama

    Liquid Chromatography with Mass Spectroscopy:

    Article Title: Organoid Intelligent Morphomics: Decoding the organoid morphome through artificial intelligence from phenotypic quantification to mechanistic insight
    Article Snippet: ional capabilities that can be leveraged for PDS, facilitating objective evaluation of therapeutic efficacy. In a seminal study, kidney organoids were deployed to screen the FDA-approved drug library (Tocriscreen), where quantitative extraction of nephron segment parameters, including volume, cell number, and spatial density, revealed that imatinib markedly attenuated cisplatin-induced tubular dama

    Nuclear Magnetic Resonance:

    Article Title: Organoid Intelligent Morphomics: Decoding the organoid morphome through artificial intelligence from phenotypic quantification to mechanistic insight
    Article Snippet: ional capabilities that can be leveraged for PDS, facilitating objective evaluation of therapeutic efficacy. In a seminal study, kidney organoids were deployed to screen the FDA-approved drug library (Tocriscreen), where quantitative extraction of nephron segment parameters, including volume, cell number, and spatial density, revealed that imatinib markedly attenuated cisplatin-induced tubular dama

    Biomarker Discovery:

    Article Title: Organoid Intelligent Morphomics: Decoding the organoid morphome through artificial intelligence from phenotypic quantification to mechanistic insight
    Article Snippet: ional capabilities that can be leveraged for PDS, facilitating objective evaluation of therapeutic efficacy. In a seminal study, kidney organoids were deployed to screen the FDA-approved drug library (Tocriscreen), where quantitative extraction of nephron segment parameters, including volume, cell number, and spatial density, revealed that imatinib markedly attenuated cisplatin-induced tubular dama



    Similar Products

    oxygen saturation  (Hamilton Company)
    98
    Hamilton Company oxygen saturation
    Oxygen Saturation, supplied by Hamilton Company, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda/OxyFerm+FDA+VP+120/10__1007_slash_s00253___026___14038___y-42-1-12
    Average 98 stars, based on 1 article reviews
    oxygen saturation - by Bioz Stars, 2026-11
    98/100 stars
    		  Buy from Supplier
    fda drug library high throughput screen  (TargetMol)
    95
    TargetMol fda drug library high throughput screen
    Fda Drug Library High Throughput Screen, supplied by TargetMol, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda/FDA-Approved+Drug+Library/pm42880285-1948-0-11
    Average 95 stars, based on 1 article reviews
    fda drug library high throughput screen - by Bioz Stars, 2026-11
    95/100 stars
    		  Buy from Supplier
    fda  (Mendeley Ltd)
    86
    Mendeley Ltd fda
    Fda, supplied by Mendeley Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda/approved+fda/pm41949508-340-3-37
    Average 86 stars, based on 1 article reviews
    fda - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    fda-approved saliva collection kit  (Color Genomics)
    90
    Color Genomics fda-approved saliva collection kit
    Fda Approved Saliva Collection Kit, supplied by Color Genomics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda/fda+approved+saliva+collection+kit/nct03762590-17-5-10
    Average 90 stars, based on 1 article reviews
    fda-approved saliva collection kit - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    fda approved drug library 96 well  (Selleck Chemicals)
    96
    Selleck Chemicals fda approved drug library 96 well
    Fda Approved Drug Library 96 Well, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda/FDA-approved+Drug+Library/pm42896551-301-150-154
    Average 96 stars, based on 1 article reviews
    fda approved drug library 96 well - by Bioz Stars, 2026-11
    96/100 stars
    		  Buy from Supplier
    fda approved therapeutic setmelanotide  (MedChemExpress)
    94
    MedChemExpress fda approved therapeutic setmelanotide
    A. Gα s activation profiling via luminescence-based cAMP accumulation assay ; B. β-arrestin 2 recruitment via NanoBiT based assay C. Shows the change in (Gα s /β-arr) signaling bias occurred upon <t>Setmelanotide</t> introduction . D. ERK activation via SRE Reporter luminescence-based assay ; E. Gα q activation via NFAT-RE Reporter luminescence-based assay ; F. Gα 12/13 activation via SRF-RE Reporter luminescence-based assay; n=3; % normalized of luminescence data in HEK293T cells; in every experiment error bar indicates ±SEM. G. Gives a comparative analysis of LogEC 50 and E max value simultaneously for each signaling profile with each of the variants which is plotted in a radar plot.
    Fda Approved Therapeutic Setmelanotide, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda/Setmelanotide/bio_rxiv__64898__2026__10__06__756976-270-35-38
    Average 94 stars, based on 1 article reviews
    fda approved therapeutic setmelanotide - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    hepg2 cells fda approved drug screening  (Selleck Chemicals)
    96
    Selleck Chemicals hepg2 cells fda approved drug screening
    A. Gα s activation profiling via luminescence-based cAMP accumulation assay ; B. β-arrestin 2 recruitment via NanoBiT based assay C. Shows the change in (Gα s /β-arr) signaling bias occurred upon <t>Setmelanotide</t> introduction . D. ERK activation via SRE Reporter luminescence-based assay ; E. Gα q activation via NFAT-RE Reporter luminescence-based assay ; F. Gα 12/13 activation via SRF-RE Reporter luminescence-based assay; n=3; % normalized of luminescence data in HEK293T cells; in every experiment error bar indicates ±SEM. G. Gives a comparative analysis of LogEC 50 and E max value simultaneously for each signaling profile with each of the variants which is plotted in a radar plot.
    Hepg2 Cells Fda Approved Drug Screening, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda/FDA-approved+Drug+Library/pm42855516-329-6-19
    Average 96 stars, based on 1 article reviews
    hepg2 cells fda approved drug screening - by Bioz Stars, 2026-11
    96/100 stars
    		  Buy from Supplier
    fda approved library  (Selleck Chemicals)
    96
    Selleck Chemicals fda approved library
    A. Gα s activation profiling via luminescence-based cAMP accumulation assay ; B. β-arrestin 2 recruitment via NanoBiT based assay C. Shows the change in (Gα s /β-arr) signaling bias occurred upon <t>Setmelanotide</t> introduction . D. ERK activation via SRE Reporter luminescence-based assay ; E. Gα q activation via NFAT-RE Reporter luminescence-based assay ; F. Gα 12/13 activation via SRF-RE Reporter luminescence-based assay; n=3; % normalized of luminescence data in HEK293T cells; in every experiment error bar indicates ±SEM. G. Gives a comparative analysis of LogEC 50 and E max value simultaneously for each signaling profile with each of the variants which is plotted in a radar plot.
    Fda Approved Library, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda/FDA-approved+Drug+Library/pm42843564-63-8-10
    Average 96 stars, based on 1 article reviews
    fda approved library - by Bioz Stars, 2026-11
    96/100 stars
    		  Buy from Supplier
    fda approved drug library  (Selleck Chemicals)
    96
    Selleck Chemicals fda approved drug library
    A. Gα s activation profiling via luminescence-based cAMP accumulation assay ; B. β-arrestin 2 recruitment via NanoBiT based assay C. Shows the change in (Gα s /β-arr) signaling bias occurred upon <t>Setmelanotide</t> introduction . D. ERK activation via SRE Reporter luminescence-based assay ; E. Gα q activation via NFAT-RE Reporter luminescence-based assay ; F. Gα 12/13 activation via SRF-RE Reporter luminescence-based assay; n=3; % normalized of luminescence data in HEK293T cells; in every experiment error bar indicates ±SEM. G. Gives a comparative analysis of LogEC 50 and E max value simultaneously for each signaling profile with each of the variants which is plotted in a radar plot.
    Fda Approved Drug Library, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda/FDA-approved+Drug+Library/pm42833216-455-17-20
    Average 96 stars, based on 1 article reviews
    fda approved drug library - by Bioz Stars, 2026-11
    96/100 stars
    		  Buy from Supplier
    fda approved compound library  (Tocris)
    95
    Tocris fda approved compound library
    A. Gα s activation profiling via luminescence-based cAMP accumulation assay ; B. β-arrestin 2 recruitment via NanoBiT based assay C. Shows the change in (Gα s /β-arr) signaling bias occurred upon <t>Setmelanotide</t> introduction . D. ERK activation via SRE Reporter luminescence-based assay ; E. Gα q activation via NFAT-RE Reporter luminescence-based assay ; F. Gα 12/13 activation via SRF-RE Reporter luminescence-based assay; n=3; % normalized of luminescence data in HEK293T cells; in every experiment error bar indicates ±SEM. G. Gives a comparative analysis of LogEC 50 and E max value simultaneously for each signaling profile with each of the variants which is plotted in a radar plot.
    Fda Approved Compound Library, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda/Tocriscreen+FDA-Approved+Drugs+Library/pm42816495-490-21-24
    Average 95 stars, based on 1 article reviews
    fda approved compound library - by Bioz Stars, 2026-11
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    A. Gα s activation profiling via luminescence-based cAMP accumulation assay ; B. β-arrestin 2 recruitment via NanoBiT based assay C. Shows the change in (Gα s /β-arr) signaling bias occurred upon Setmelanotide introduction . D. ERK activation via SRE Reporter luminescence-based assay ; E. Gα q activation via NFAT-RE Reporter luminescence-based assay ; F. Gα 12/13 activation via SRF-RE Reporter luminescence-based assay; n=3; % normalized of luminescence data in HEK293T cells; in every experiment error bar indicates ±SEM. G. Gives a comparative analysis of LogEC 50 and E max value simultaneously for each signaling profile with each of the variants which is plotted in a radar plot.

    Journal: bioRxiv

    Article Title: Sparsely Phosphorylable Residues, Tuned by Agonist Chemotype, Shapes GPCR Signaling

    doi: 10.64898/2026.10.06.756976

    Figure Lengend Snippet: A. Gα s activation profiling via luminescence-based cAMP accumulation assay ; B. β-arrestin 2 recruitment via NanoBiT based assay C. Shows the change in (Gα s /β-arr) signaling bias occurred upon Setmelanotide introduction . D. ERK activation via SRE Reporter luminescence-based assay ; E. Gα q activation via NFAT-RE Reporter luminescence-based assay ; F. Gα 12/13 activation via SRF-RE Reporter luminescence-based assay; n=3; % normalized of luminescence data in HEK293T cells; in every experiment error bar indicates ±SEM. G. Gives a comparative analysis of LogEC 50 and E max value simultaneously for each signaling profile with each of the variants which is plotted in a radar plot.

    Article Snippet: The synthetic pharmacological panel, which included Melanotan I (MT-I; MedChemExpress, cat. no. HYN2466), Melanotan II (MT-II; MedChemExpress, cat. no. HYP0267), Bremelanotide (MedChemExpress, cat. no. SML2756), the small-molecule agonist THIQ (Sigma-Aldrich, cat. no. SML2449), and the FDA-approved therapeutic Setmelanotide (MedChemExpress, cat. no. HY-19870), were all purchased.

    Techniques: Activation Assay, Profiling, Luminescence Assay, Analysis, Luciferase

    Journal: bioRxiv

    Article Title: Sparsely Phosphorylable Residues, Tuned by Agonist Chemotype, Shapes GPCR Signaling

    doi: 10.64898/2026.10.06.756976

    Figure Lengend Snippet: Calculation of receptor mediated bias factor with its FDA approved ligand Setmelanotide

    Article Snippet: The synthetic pharmacological panel, which included Melanotan I (MT-I; MedChemExpress, cat. no. HYN2466), Melanotan II (MT-II; MedChemExpress, cat. no. HYP0267), Bremelanotide (MedChemExpress, cat. no. SML2756), the small-molecule agonist THIQ (Sigma-Aldrich, cat. no. SML2449), and the FDA-approved therapeutic Setmelanotide (MedChemExpress, cat. no. HY-19870), were all purchased.

    Techniques: